1
|
Pasquier E, Rosendahl J, Solberg A, Ståhlberg A, Håkansson J, Chinga-Carrasco G. Polysaccharides and Structural Proteins as Components in Three-Dimensional Scaffolds for Breast Cancer Tissue Models: A Review. Bioengineering (Basel) 2023; 10:682. [PMID: 37370613 DOI: 10.3390/bioengineering10060682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 05/26/2023] [Accepted: 05/30/2023] [Indexed: 06/29/2023] Open
Abstract
Breast cancer is the most common cancer among women, and even though treatments are available, efficiency varies with the patients. In vitro 2D models are commonly used to develop new treatments. However, 2D models overestimate drug efficiency, which increases the failure rate in later phase III clinical trials. New model systems that allow extensive and efficient drug screening are thus required. Three-dimensional printed hydrogels containing active components for cancer cell growth are interesting candidates for the preparation of next generation cancer cell models. Macromolecules, obtained from marine- and land-based resources, can form biopolymers (polysaccharides such as alginate, chitosan, hyaluronic acid, and cellulose) and bioactive components (structural proteins such as collagen, gelatin, and silk fibroin) in hydrogels with adequate physical properties in terms of porosity, rheology, and mechanical strength. Hence, in this study attention is given to biofabrication methods and to the modification with biological macromolecules to become bioactive and, thus, optimize 3D printed structures that better mimic the cancer cell microenvironment. Ink formulations combining polysaccharides for tuning the mechanical properties and bioactive polymers for controlling cell adhesion is key to optimizing the growth of the cancer cells.
Collapse
Affiliation(s)
- Eva Pasquier
- RISE PFI AS, Høgskoleringen 6b, NO-7491 Trondheim, Norway
| | - Jennifer Rosendahl
- RISE Unit of Biological Function, Division Materials and Production, RISE Research Institutes of Sweden, Box 857, 50115 Borås, Sweden
| | - Amalie Solberg
- RISE PFI AS, Høgskoleringen 6b, NO-7491 Trondheim, Norway
| | - Anders Ståhlberg
- Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, 41390 Gothenburg, Sweden
- Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden
| | - Joakim Håkansson
- RISE Unit of Biological Function, Division Materials and Production, RISE Research Institutes of Sweden, Box 857, 50115 Borås, Sweden
- Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden
- Department of Chemistry and Molecular Biology, University of Gothenburg, 40530 Gothenburg, Sweden
| | | |
Collapse
|
2
|
Dankó T, Petővári G, Raffay R, Sztankovics D, Moldvai D, Vetlényi E, Krencz I, Rókusz A, Sipos K, Visnovitz T, Pápay J, Sebestyén A. Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting. Int J Mol Sci 2022; 23:ijms23137444. [PMID: 35806452 PMCID: PMC9267600 DOI: 10.3390/ijms23137444] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/26/2022] [Accepted: 06/27/2022] [Indexed: 02/07/2023] Open
Abstract
Monolayer cultures, the less standard three-dimensional (3D) culturing systems, and xenografts are the main tools used in current basic and drug development studies of cancer research. The aim of biofabrication is to design and construct a more representative in vivo 3D environment, replacing two-dimensional (2D) cell cultures. Here, we aim to provide a complex comparative analysis of 2D and 3D spheroid culturing, and 3D bioprinted and xenografted breast cancer models. We established a protocol to produce alginate-based hydrogel bioink for 3D bioprinting and the long-term culturing of tumour cells in vitro. Cell proliferation and tumourigenicity were assessed with various tests. Additionally, the results of rapamycin, doxycycline and doxorubicin monotreatments and combinations were also compared. The sensitivity and protein expression profile of 3D bioprinted tissue-mimetic scaffolds showed the highest similarity to the less drug-sensitive xenograft models. Several metabolic protein expressions were examined, and the in situ tissue heterogeneity representing the characteristics of human breast cancers was also verified in 3D bioprinted and cultured tissue-mimetic structures. Our results provide additional steps in the direction of representing in vivo 3D situations in in vitro studies. Future use of these models could help to reduce the number of animal experiments and increase the success rate of clinical phase trials.
Collapse
Affiliation(s)
- Titanilla Dankó
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Gábor Petővári
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Regina Raffay
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Dániel Sztankovics
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Dorottya Moldvai
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Enikő Vetlényi
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Ildikó Krencz
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - András Rókusz
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Krisztina Sipos
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Tamás Visnovitz
- Department of Genetics, Cell- and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary;
- Department of Plant Physiology and Molecular Plant Biology, ELTE Eötvös Loránd University, Pázmány Péter Sétány 1/c, 1117 Budapest, Hungary
| | - Judit Pápay
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
| | - Anna Sebestyén
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, 1085 Budapest, Hungary; (T.D.); (G.P.); (R.R.); (D.S.); (D.M.); (E.V.); (I.K.); (A.R.); (K.S.); (J.P.)
- Correspondence: or
| |
Collapse
|
3
|
Pérez Piñero C, Giulianelli S, Lamb CA, Lanari C. New Insights in the Interaction of FGF/FGFR and Steroid Receptor Signaling in Breast Cancer. Endocrinology 2022; 163:6491899. [PMID: 34977930 DOI: 10.1210/endocr/bqab265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Indexed: 11/19/2022]
Abstract
Luminal breast cancer (BrCa) has a favorable prognosis compared with other tumor subtypes. However, with time, tumors may evolve and lead to disease progression; thus, there is a great interest in unraveling the mechanisms that drive tumor metastasis and endocrine resistance. In this review, we focus on one of the many pathways that have been involved in tumor progression, the fibroblast growth factor/fibroblast growth factor receptor (FGFR) axis. We emphasize in data obtained from in vivo experimental models that we believe that in luminal BrCa, tumor growth relies in a crosstalk with the stromal tissue. We revisited the studies that illustrate the interaction between hormone receptors and FGFR. We also highlight the most frequent alterations found in BrCa cell lines and provide a short review on the trials that use FGFR inhibitors in combination with endocrine therapies. Analysis of these data suggests there are many players involved in this pathway that might be also targeted to decrease FGF signaling, in addition to specific FGFR inhibitors that may be exploited to increase their efficacy.
Collapse
Affiliation(s)
- Cecilia Pérez Piñero
- Instituto de Biología y Medicina Experimental, IBYME CONICET, C1428ADN Ciudad de Buenos Aires, Argentina
| | - Sebastián Giulianelli
- Instituto de Biología y Medicina Experimental, IBYME CONICET, C1428ADN Ciudad de Buenos Aires, Argentina
- Instituto de Biología de Organismos Marinos, IBIOMAR-CCT CENPAT-CONICET, U9120ACD Puerto Madryn, Argentina
| | - Caroline A Lamb
- Instituto de Biología y Medicina Experimental, IBYME CONICET, C1428ADN Ciudad de Buenos Aires, Argentina
| | - Claudia Lanari
- Instituto de Biología y Medicina Experimental, IBYME CONICET, C1428ADN Ciudad de Buenos Aires, Argentina
| |
Collapse
|
4
|
Nam K, Jeong CB, Kim H, Ahn M, Ahn S, Hur H, Kim DU, Jang J, Gwon H, Lim Y, Cho D, Lee K, Bae JY, Chang KS. Quantitative Photothermal Characterization with Bioprinted 3D Complex Tissue Constructs for Early-Stage Breast Cancer Therapy Using Gold Nanorods. Adv Healthc Mater 2021; 10:e2100636. [PMID: 34235891 DOI: 10.1002/adhm.202100636] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 06/18/2021] [Indexed: 11/12/2022]
Abstract
Plasmonic photothermal therapy (PPTT) using gold nanoparticles (AuNPs) has shown great potential for use in selective tumor treatment, because the AuNPs can generate destructive heat preferentially upon irradiation. However, PPTT using AuNPs has not been added to practice, owing to insufficient heating methods and tissue temperature measurement techniques, leading to unreliable and inaccurate treatments. Because the photothermal properties of AuNPs vary with laser power, particle optical density, and tissue depth, the accurate prediction of heat generation is indispensable for clinical treatment. In this report, bioprinted 3D complex tissue constructs comprising processed gel obtained from porcine skin and human decellularized adipose tissue are presented for characterization of the photothermal properties of gold nanorods (AuNRs) having an aspect ratio of 3.7 irradiated by a near-infrared laser. Moreover, an analytical function is suggested for achieving PPTT that can cause thermal damage selectively on early-stage human breast cancer by regulating the heat generation of the AuNRs in the tissue.
Collapse
Affiliation(s)
- Ki‐Hwan Nam
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Chan Bae Jeong
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - HyeMi Kim
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Minjun Ahn
- Department of Mechanical Engineering Pohang University of Science and Technology (POSTECH) Pohang Kyungbuk 37673 Republic of Korea
| | - Sung‐Jun Ahn
- Research Division for Industry and Environment Korea Atomic Energy Research Institute (KAERI) Jeongeup Jeollabuk‐do 56212 Republic of Korea
| | - Hwan Hur
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Dong Uk Kim
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Jinah Jang
- Department of Creative IT Engineering School of Interdisciplinary Bioscience and Bioengineering Pohang University of Science and Technology (POSTECH) Pohang Kyungbuk 37673 Republic of Korea
| | - Hui‐Jeong Gwon
- Research Division for Industry and Environment Korea Atomic Energy Research Institute (KAERI) Jeongeup Jeollabuk‐do 56212 Republic of Korea
| | - Youn‐Mook Lim
- Research Division for Industry and Environment Korea Atomic Energy Research Institute (KAERI) Jeongeup Jeollabuk‐do 56212 Republic of Korea
| | - Dong‐Woo Cho
- Department of Mechanical Engineering Pohang University of Science and Technology (POSTECH) Pohang Kyungbuk 37673 Republic of Korea
| | - Kye‐Sung Lee
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Ji Yong Bae
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| | - Ki Soo Chang
- Center for Scientific Instrumentation Division of Scientific Instrumentation and Management Korea Basic Science Institute (KBSI) Daejeon 34133 Republic of Korea
| |
Collapse
|
5
|
Jia Y, Li J, Chen J, Hu P, Jiang L, Chen X, Huang M, Chen Z, Xu P. Smart Photosensitizer: Tumor-Triggered Oncotherapy by Self-Assembly Photodynamic Nanodots. ACS Appl Mater Interfaces 2018; 10:15369-15380. [PMID: 29652473 DOI: 10.1021/acsami.7b19058] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Clinical photosensitizers suffer from the disadvantages of fast photobleaching and high systemic toxicities because of the off-target photodynamic effects. To address these problems, we report a self-assembled pentalysine-phthalocyanine assembly nanodots (PPAN) fabricated by an amphipathic photosensitizer-peptide conjugate. We triggered the photodynamic therapy effects of photosensitizers by precisely controlling the assembly and disintegration of the nanodots. In physiological aqueous conditions, PPAN exhibited a size-tunable spherical conformation with a highly positive shell of the polypeptides and a hydrophobic core of the π-stacking Pc moieties. The assembly conformation suppressed the fluorescence and the reactive oxygen species generation of the monomeric photosensitizer molecules (mono-Pc) and thus declined the photobleaching and off-target photodynamic effects. However, tumor cells disintegrated PPAN and released the mono-Pc molecules, which exhibited fluorescence for detection and the photodynamic effects for the elimination of the tumor tissues. The molecular dynamics simulations revealed the various assembly configurations of PPAN and illustrated the assembly mechanism. At the cellular level, PPAN exhibited a remarkable phototoxicity to breast cancer cells with the IC50 values in a low nanomolar range. By using the subcutaneous and orthotopic breast cancer animal models, we also demonstrated the excellent antitumor efficacies of PPAN in vivo.
Collapse
Affiliation(s)
- Yuhua Jia
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
- College of Life Science , Fujian Agriculture and Forestry University , Fuzhou , Fujian 350002 , P. R. China
| | - Jinyu Li
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Jincan Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Ping Hu
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Longguang Jiang
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Xueyuan Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Mingdong Huang
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Zhuo Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Peng Xu
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| |
Collapse
|
6
|
van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ. Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 2018; 38:140S-150S. [PMID: 29554468 PMCID: PMC5862071 DOI: 10.1177/0272989x17718168] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The UK Age trial compared annual mammography screening of women ages 40 to 49 years with no screening and found a statistically significant breast cancer mortality reduction at the 10-year follow-up but not at the 17-year follow-up. The objective of this study was to compare the observed Age trial results with the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer model predicted results. METHODS Five established CISNET breast cancer models used data on population demographics, screening attendance, and mammography performance from the Age trial together with extant natural history parameters to project breast cancer incidence and mortality in the control and intervention arm of the trial. RESULTS The models closely reproduced the effect of annual screening from ages 40 to 49 years on breast cancer incidence. Restricted to breast cancer deaths originating from cancers diagnosed during the intervention phase, the models estimated an average 15% (range across models, 13% to 17%) breast cancer mortality reduction at the 10-year follow-up compared with 25% (95% CI, 3% to 42%) observed in the trial. At the 17-year follow-up, the models predicted 13% (range, 10% to 17%) reduction in breast cancer mortality compared with the non-significant 12% (95% CI, -4% to 26%) in the trial. CONCLUSIONS The models underestimated the effect of screening on breast cancer mortality at the 10-year follow-up. Overall, the models captured the observed long-term effect of screening from age 40 to 49 years on breast cancer incidence and mortality in the UK Age trial, suggesting that the model structures, input parameters, and assumptions about breast cancer natural history are reasonable for estimating the impact of screening on mortality in this age group.
Collapse
Affiliation(s)
| | | | - Jeanne S Mandelblatt
- Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington DC, USA
| | - Hui Huang
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School Boston, Boston, MA, USA
| | - Mehmet Ali Ergun
- Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA
| | - Elizabeth S Burnside
- Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Cong Xu
- Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA
| | - Yisheng Li
- Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Oguzhan Alagoz
- Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA
| | - Sandra J Lee
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School Boston, Boston, MA, USA
| | - Natasha K Stout
- Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
| | - Juhee Song
- Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Amy Trentham-Dietz
- Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA
| | - Sylvia K Plevritis
- Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA
| | - Sue M Moss
- Department of cancer prevention, Wolfson Institute, Queen Mary University of London, London, UK
| | - Harry J de Koning
- Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands
| |
Collapse
|
7
|
Fabris V, Abascal MF, Giulianelli S, May M, Sequeira GR, Jacobsen B, Lombès M, Han J, Tran L, Molinolo A, Lanari C. Isoform specificity of progesterone receptor antibodies. J Pathol Clin Res 2017; 3:227-233. [PMID: 29085663 PMCID: PMC5653926 DOI: 10.1002/cjp2.83] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 09/06/2017] [Accepted: 09/08/2017] [Indexed: 12/19/2022]
Abstract
Progesterone receptors (PR) are prognostic and predictive biomarkers in hormone‐dependent cancers. Two main PR isoforms have been described, PRB and PRA, that differ only in that PRB has 164 extra N‐terminal amino acids. It has been reported that several antibodies empirically exclusively recognize PRA in formalin‐fixed paraffin‐embedded (FFPE) tissues. To confirm these findings, we used human breast cancer xenograft models, T47D‐YA and ‐YB cells expressing PRA or PRB, respectively, MDA‐MB‐231 cells modified to synthesize PRB, and MDA‐MB‐231/iPRAB cells which can bi‐inducibly express either PRA or PRB. Cells were injected into immunocompromised mice to generate tumours exclusively expressing PRA or PRB. PR isoform expression was verified using immunoblots. FFPE samples from the same tumours were studied by immunohistochemistry using H‐190, clone 636, clone 16, and Ab‐6 anti‐PR antibodies, the latter exclusively recognizing PRB. Except for Ab‐6, all antibodies displayed a similar staining pattern. Our results indicate that clones 16, 636, and the H‐190 antibody recognize both PR isoforms. They point to the need for more stringency in evaluating the true specificity of purported PRA‐specific antibodies as the PRA/PRB ratio may have prognostic and predictive value in breast cancer.
Collapse
Affiliation(s)
- Victoria Fabris
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina
| | - María F Abascal
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina
| | - Sebastián Giulianelli
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina.,Laboratorio de Reproducción y Biología Integrativa de Invertebrados Marinos, Instituto de Biología de Organismos Marinos (IBIOMAR), CONICETArgentina
| | - María May
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina
| | - Gonzalo R Sequeira
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina
| | | | - Marc Lombès
- Unité Mixte de Recherche, INSERM U 1185, Fac Med Paris SudUniversité Paris SaclayFrance
| | - Julie Han
- Department of Pathology, Moore's Cancer Center, UCSDLa JollaCAUSA
| | - Luan Tran
- Department of Pathology, Moore's Cancer Center, UCSDLa JollaCAUSA
| | - Alfredo Molinolo
- Department of Pathology, Moore's Cancer Center, UCSDLa JollaCAUSA
| | - Claudia Lanari
- Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), CONICETBuenos AiresArgentina
| |
Collapse
|